Press

High-tech and humanity – robotic assistance enters intensive care units

April 22, 2021

Intelligent, assistive robotics for early mobilization of critically illintensive care patients convinces investors. Fighting the shortage of nurses with cutting-edge technology.

Supporting nurses, accelerating recovery. Reactive Robotics employs its robotic assistance system to treat, among others, Covid-19 patients in intensive care units, to enable these patients in recovering faster. The company has now raised a mid-seven-figure sum in a financing round.

In addition to the existing investors, the company was able to gain another strategic investor: Henrik Schunk Beteiligungen GmbH. The fact that Reactive Robotics’ technology is convincing is also demonstrated by the renewed participation of the existing shareholders Bayern Kapital, High-Tech Gründerfonds, Dr. Doll Holding and the TQ Group. The new investment enables the Munich-based company to further develop the market potential of intelligent, assistive robotics for early mobilization therapy of intensive care patients, especially on a broad national and international level.

Studies at the Charité in Berlin, the Schön Klinik Bad Aibling and many other hospitals dramatically confirm that the agile team around founder Dr. Alexander König is on the right track with the development of the VEMO® system.

The VEMO® system relieves nursing and therapy staff of their physically difficult work through technology, leaving more room for human attention. The intensive care bed becomes a therapy device – patients receive therapy directly in their intensive care bed. The sensors and intelligence of the robot support the therapist in the “therapy dosage” – the dangerous patient transfer onto a separate therapy device is no longer necessary.

Due to the stringent “Quality First” approach, Reactive Robotics was one of the first medical technology companies to receive certification according to the European Medical Device Regulation (MDR) in August 2020 – another important step in implementing the ambition to become the “standard of care” in early mobilization in the future.


About Reactive Robotics GmbH
Reactive Robotics was founded in April 2015 in Munich with the goal to provide the best possible early mobilization to critically ill intensive care patients. The team around the founder, Dr. Alexander König, received the CE approval for their robotic therapy system VEMO® in 2019. Since 2020, the company’s robots have been providing therapy to patients in need of intensive care in various hospitals.

Contact
Dr. Alexander König
Landsberger Straße 234 | 80687 Munich, Germany
+49 89 9604 03301
alexander.koenig@reactive-robotics.com
www.reactive-robotics.com

About Dr. Doll Holding GmbH
Dr. Doll Holding under the management of Dr. Theo Doll holds shares in companies from the field of plastics technology, as well as from the field of automation and robotics. Doll Holding invests in startups in the field of robotics and vision technology.

Contact
Dr. Theo Doll
Industriestraße 29 | 74193 Schwaigern
+49 7138 812 200
t.doll@sohner-worldwide.com

About MTIP
MTIP is a growing pan-European health-tech growth investor based in Basel, Switzerland. We invest in digital health and digitally connected medical technology companies whose offerings provide clear health-related and economic value. Our investment team, which has extensive private equity expertise, actively works with our portfolio companies to help them grow. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors.

Contact
Dr. Christoph Kausch
Dufourstrasse 49 | CH-4052 Basel | Switzerland
+41 61 551 02 50
christoph.kausch@mtip.ch
www.mtip.ch

About Bayern Kapital
Bayern Kapital GmbH, based in Landshut, was founded in 1995 on the initiative of the Bavarian State Government as a wholly owned subsidiary of LfA Förderbank Bayern. As the venture capital company of the State of Bavaria, Bayern Kapital provides equity capital to the founders of innovative high-tech companies and young, innovative technology companies in Bavaria. Bayern Kapital currently manages twelve investment funds with an investment volume of around 500 million euros.

To date, Bayern Kapital has invested around 350 million euros of venture capital in some 290 innovative technology-oriented companies from a wide range of sectors, including life sciences, software & IT, materials & new materials, nanotechnology and environmental technology. As a result, more than 8,000 jobs have been permanently created in Bavaria in companies with a promising future.
www.bayernkapital.de

Press Contact
IWK Communication Partner
Ira Wülfing / Dominik Neumüller Ohmstraße 1 | DE-80802 Munich
+49 89 2000 30-30
bayernkapital@iwk-cp.com
www.iwk-cp.com

About TQ-Group
TQ-Group was founded in 1994 as a 2-man company and today consists of around 1,700 employees at 15 locations in Germany, Switzerland, the USA and China. As one of the largest technology service providers and electronics specialists in Germany, the TQ-Group implements customized and innovative solutions for a wide range of industries, both in the hardware and software sectors – from development, production and other services to product lifecycle management.

This means: TQ offers competence, experience and vision for the areas of E²MS, embedded modules, electronic drives, energy management, medical technology, aviation and robotics. TQ is also consistently growing with a diverse product portfolio of proprietary products in the economic current megatrends such as digitalization, Industry 4.0, artificial intelligence, e-mobility. The TQ Group also combines both as an ODM (Original Design Manufacturer).

Customer-specific products are developed and produced internationally on the basis of the service and solution modular system. And all of this is “Made in Germany”. In fiscal year 2019/2020, the owner-managed company’s total global sales amounted to over 289 million euros.
www.tq-group.com

Press contact
TQ-Systems GmbH Michael Horky
Mühlstraße 2 | 82229 Seefeld
+49 8153 9308-0
michael.horky@tq-group.com
www.tq-group.com

About Henrik Schunk Beteiligungen GmbH
Henrik Schunk
Bahnhofstraße 106-134 | 74348 Lauffen am Neckar

About High-Tech Gründerfonds
The seed investor High-Tech Gründerfonds (HTGF) finances technology start-ups with growth potential. With a volume of around 900 million euros spread across three funds and an international partner network, HTGF has supported more than 600 start-ups since 2005. Its team of experienced investment managers and start-up experts supports the young companies with know-how, entrepreneurial spirit and passion. The focus is on high-tech start- ups in the fields of digital tech, industrial tech, life sciences, chemicals and related business areas. Nearly €3 billion in capital has been invested in the HTGF portfolio by external investors in more than 1,700 follow-on financing rounds to date. In addition, the fund has already successfully sold shares in more than 120 companies.

Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies.  The Fund Investors

Media contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter
Head of Marketing & Communications
+49 228 82300 – 188
s.grueter@htgf.de

Contact
High-Tech Gründerfonds Management GmbH
Marco Winzer
Schlegelstraße 2 | 53113 Bonn
+49 228 823001-06
+49 228 823000-50
m.winzer@htgf.de
www.high-tech-gruenderfonds.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017. Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
 
Press
25. March 2024

Growth push for CI HUB GmbH, Catalyzing Innovation in Content Integration Solutions

Potsdam, 25.03.2024 – Scale Capital, a Danish early stage technology investor with a focus on helping companies accelerate growth in the US market, has announced its investment in CI HUB GmbH, a leading provider of content integration solutions. This significant seven-figure amount from new and existing investors marks a milestone in CI HUB’s journey towards revolutionizing the way corporates and creatives access digital assets and data. CI HUB specializes in developing innovative
 
Press
20. March 2024

graswald.ai raises $3.3M seed round to scale the way brands create 3D content with AI

The Hannover-based start-up has secured seed funding to build Canva for 3D, leveraging generative AI to transform 3D creative processes for 3D product visualisation. Hannover, 20 March 2024 – graswald.ai announced the close of a $3.3 million seed round led by existing investor Lakestar as well as Supernode Global with continued support from existing investor HTGF and further participation from Spatial Computing expert FOV Ventures, Robin Capital, Angel Invest Ventures and Notion Sc